Heparin-induced thrombocytopenia

100,051views

Heparin-induced thrombocytopenia

Block 2

Block 2

Pentose phosphate pathway
Diabetes mellitus
Disorders of carbohydrate metabolism: Pathology review
Amino acid metabolism
Disorders of amino acid metabolism: Pathology review
Dyslipidemias: Pathology review
Drug misuse, intoxication and withdrawal: Alcohol: Pathology review
Diabetes mellitus (Type 2): Clinical sciences
Fatty acid synthesis
Wernicke-Korsakoff syndrome
Alcohol-induced hepatitis: Clinical sciences
Diabetes mellitus: Clinical
Diabetes mellitus (Type 1): Clinical sciences
Fetal alcohol syndrome
Diabetes mellitus: Pathology review
Alcohol use disorder
Alcohol-associated liver disease
Enterococcus
Staphylococcus epidermidis
Mycobacterium tuberculosis (Tuberculosis)
Neisseria gonorrhoeae
Corynebacterium diphtheriae (Diphtheria)
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Water-soluble vitamin deficiency and toxicity: B9, B12 and vitamin C: Pathology review
Vitamin D
Klebsiella pneumoniae
Vitamin B12 deficiency
Folate (Vitamin B9) deficiency
Streptococcus viridans
Clostridium perfringens
Chlamydia trachomatis
Staphylococcus saprophyticus
Staphylococcus aureus
Mycobacterium leprae
Clostridium botulinum (Botulism)
Bacillus anthracis (Anthrax)
Actinomyces israelii
Clostridium tetani (Tetanus)
Streptococcus agalactiae (Group B Strep)
Bacillus cereus (Food poisoning)
Listeria monocytogenes
Pseudomonas aeruginosa
Nocardia
Haemophilus influenzae
Neisseria meningitidis
Treponema pallidum (Syphilis)
Human papillomavirus
Herpes simplex virus
Neuraminidase inhibitors
Human herpesvirus 6 (Roseola)
Borrelia burgdorferi (Lyme disease)
Adenovirus
Yersinia pestis (Plague)
Rhinovirus
Rubella virus
Influenza virus
Mumps virus
Measles virus
Human herpesvirus 8 (Kaposi sarcoma)
Herpesvirus medications
Plasmodium species (Malaria)
Coxiella burnetii (Q fever)
Ehrlichia and Anaplasma
Bartonella henselae (Cat-scratch disease and Bacillary angiomatosis)
Rickettsia rickettsii (Rocky Mountain spotted fever) and other Rickettsia species
Anthelmintic medications
Antimalarials
Trypanosoma cruzi (Chagas disease)
Francisella tularensis (Tularemia)
Candida
Anti-mite and louse medications
Miscellaneous antifungal medications
Azoles
Cytokines
Type I hypersensitivity
Type II hypersensitivity
Type III hypersensitivity
Type IV hypersensitivity
Hyper IgM syndrome
Leukocyte adhesion deficiency
Chronic granulomatous disease
X-linked agammaglobulinemia
Wound healing
Complement deficiency
Inflammation
Pulmonary corticosteroids and mast cell inhibitors
Selective immunoglobulin A deficiency
Necrosis and apoptosis
Ischemia
Wiskott-Aldrich syndrome
Immunodeficiencies: Clinical
Non-corticosteroid immunosuppressants and immunotherapies
Intrinsic hemolytic normocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Blood groups and transfusions
Macrocytic anemia: Pathology review
Cytomegalovirus infection after transplant (NORD)
Glucocorticoids
Blood products and transfusion: Clinical
Acute intermittent porphyria
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Aplastic anemia
Sideroblastic anemia
Microcytic anemia: Pathology review
Erythropoietin
Post-transplant lymphoproliferative disorders (NORD)
Platelet disorders: Pathology review
Thrombotic thrombocytopenic purpura
Neonatal jaundice: Clinical
Jaundice: Clinical
Mixed platelet and coagulation disorders: Pathology review
Von Willebrand disease
Immune thrombocytopenia
Hemolytic-uremic syndrome
Extrinsic hemolytic normocytic anemia: Pathology review
Jaundice
Iron deficiency anemia
Anemia: Clinical
Graft-versus-host disease
Iron deficiency anemia: Clinical sciences
Autoimmune hemolytic anemia
Severe chronic neutropenia (NORD)
Anemia of chronic disease: Year of the Zebra
Jaundice: Pathology review
Blood transfusion reactions and transplant rejection: Pathology review
Anemia of chronic disease
Non-hemolytic normocytic anemia: Pathology review
Antimetabolites: Sulfonamides and trimethoprim
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Fluoroquinolones
Protein synthesis inhibitors: Aminoglycosides
Nucleotide metabolism
Adenosine deaminase deficiency
Purine and pyrimidine synthesis and metabolism disorders: Pathology review
Gout
Gout and pseudogout: Pathology review
Lesch-Nyhan syndrome
Gout: Clinical sciences
Oncogenes and tumor suppressor genes
Anti-tumor antibiotics
Blood histology
DNA synthesis inhibitors: Metronidazole
Deep vein thrombosis
Disseminated intravascular coagulation
Factor V Leiden
Protein C deficiency
Protein S deficiency
Miscellaneous cell wall synthesis inhibitors
Miscellaneous protein synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Antithrombin III deficiency
Heparin-induced thrombocytopenia
Antiphospholipid syndrome
Hemophilia
Hemophilia: Year of the Zebra
Protease inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Hepatitis medications
HIV and AIDS: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Mechanisms of antibiotic resistance
Coagulation disorders: Pathology review
Integrase and entry inhibitors
Leukemias: Pathology review
Myeloproliferative disorders: Pathology review
Lymphomas: Pathology review
Chronic leukemia
Acute leukemia
Non-Hodgkin lymphoma
Polycythemia vera (NORD)
Myelodysplastic syndromes
Hodgkin lymphoma
Essential thrombocythemia (NORD)
Waldenstrom macroglobulinemia
Multiple myeloma: Clinical sciences
Mastocytosis (NORD)
Plasma cell disorders: Pathology review
Plasma cell disorders: Clinical
Spleen histology
Myelofibrosis (NORD)
Lymphoma: Clinical
Varicella zoster virus
Coxsackievirus
Congenital TORCH infections: Pathology review
Streptococcus pyogenes (Group A Strep)
Lyme disease: Clinical sciences
Cortisol
Hematopoietic medications
Parvovirus B19
HIV (AIDS)
Zika virus

Transcript

Watch video only

The term heparin-induced thrombocytopenia can be divided into two parts.

Heparin refers to an anticoagulant medication which prevents blood clots from forming, and thrombocytopenia refers to decreased number of thrombocytes, or platelets, in the blood.

So, heparin-induced thrombocytopenia or, HIT, is a complication caused by heparin that results in decreased platelets in the blood.

Okay, so imagine you’re making dinner and accidentally cut one of your fingers.

Now, if your body doesn’t stop the bleeding, you will keep losing blood until there’s not enough to supply the vital organs like the heart and brain.

Now to prevent this from happening the body has a process called hemostasis.

This process has two phases: primary and secondary hemostasis.

In primary hemostasis, platelets aggregate to form a plug at the site of an injured blood vessel.

While these platelets are aggregating, coagulation, or secondary hemostasis starts.

This is where numerous enzymes that are always floating around in the blood called clotting factors get proteolytically activated, meaning that activation happens when a small piece is chopped off - a bit like pulling the pin out of a grenade.

These factors activate one another, eventually leading to the activation of fibrin or factor Ia.

That results in a fibrin mesh which forms around the platelet plug to reinforce it and hold it together.

Without primary and secondary hemostasis, our body would suffer massive blood loss from even the most minor injuries; imagine losing all of your blood from something as simple as a pinprick!

Okay, so heparin induced thrombocytopenia is caused by heparin.

This medication works by activating an enzyme called antithrombin III, which inhibits coagulation factors Xa, also known as thrombin.

This halts secondary hemostasis and prevents existing blood clots from growing larger, so it’s often given to people who suffer from pulmonary embolisms, strokes, and myocardial infarctions.

Now, the main mechanism behind the development of HIT is actually an immune response, which starts when heparin binds to a protein on the surface of inactivated platelets called platelet factor 4 or PF-4. Together they form a complex called heparin-PF4 complex.

This complex is immunogenic in certain people, meaning they have circulating IgG antibodies that recognize the complex as foreign pathogens.

So these antibodies will bind to the heparin-PF4 complex and mark it for destruction within the spleen.

Now when the antibody binds, it causes the platelet to activate.

The activated platelets release procoagulant chemicals like thromboxane A2 or TXA2, which causes other platelets to activate.

At the same time, the original platelet will also release more PF-4s so more antibodies will bind and keep it activated.

These events leads to more and more platelets getting activated and they start forming clots throughout the body.

This way, a lot of the remaining platelets also get consumed, which results in a low platelet count.

Key Takeaways

Heparin-induced thrombocytopenia (HIT) is a rare but potentially life-threatening complication that can occur during the treatment course with heparin. HIT occurs when the body produces antibodies against heparin, which then attach to and damage platelets (the cells that help the blood clot). This can decrease the number of platelets in the blood (thrombocytopenia), which can cause easy bruising and bleeding.

Sources

  1. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  2. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  3. "Yen & Jaffe's Reproductive Endocrinology" Saunders W.B. (2018)
  4. "Bates' Guide to Physical Examination and History Taking" LWW (2016)
  5. "Robbins Basic Pathology" Elsevier (2017)
  6. "Heparin-induced thrombocytopenia: an update" Thrombosis Journal (2005)
  7. "Signaling During Platelet Adhesion and Activation" Arteriosclerosis, Thrombosis, and Vascular Biology (2010)
  8. "von Willebrand Disease in the Pediatric and Adolescent Population" Journal of Pediatric and Adolescent Gynecology (2010)